SCHEMBL3940960

SCHEMBL3940960

Clc1cccc(Cl)c1Nc1nc2c(Nc3ccccc3)ncnc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 17/20 1.00
ADORA3 P0DMS8 1/20 0.64
ADORA2A P29274 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14289511 0.86 TRPV1 (0.76) TRPV1ADORA3ADORA2A
SCHEMBL14289435 0.86 TRPV1 (1.00) TRPV1
SCHEMBL14289432 0.86 TRPV1 (1.00) TRPV1
SCHEMBL14289484 0.84 TRPV1 (1.00) TRPV1
SCHEMBL5108347 0.83 TRPV1 (0.71) TRPV1
SCHEMBL3930188 0.83 TRPV1 (1.00) TRPV1
SCHEMBL3938382 0.81 TRPV1 (0.79) TRPV1
SCHEMBL5115032 0.81 TRPV1 (0.80) TRPV1
SCHEMBL5116505 0.81 TRPV1 (0.68) TRPV1
SCHEMBL14289434 0.81 TRPV1 (1.00) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044086-A2 THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-08 EP claimed
WO-2008005303-A2 THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-10 WO claimed
WO-2008005303-A2 THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-10 WO disclosed
US-20080004253-A1 Thiazolopyrimidine modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 US disclosed
US-20080004253-A1 Thiazolopyrimidine modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004253-A1 Thiazolopyrimidine modulators of TRPV1 TRPV1, TRPA1, TRPV2 TRPV1 1/4885ADORA3 819/4885ADORA2A 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.